Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Regeneron Worries Rise On Eylea Combo Failure, Eyes Turn To PANORAMA

Executive Summary

Failure of RUBY and ONYX combo trials with Eylea and nesvacumab fan concerns over longer-term growth prospects for Regeneron's ophthalmic franchise.

You may also be interested in...



PANORAMA Helps Regeneron's Eylea Even Score With Roche's Lucentis

Phase III PANORAMA looks good, so far, for Regeneron's Eylea in diabetic retinopathy without edema.

The Year's Clinical Trials In Review: Big Misses In 2017

The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.

Stock Scan November 2017: Generics get volatile

Generic drug producers endured very mixed fortunes on the world's stock markets, with firms ending November at opposite ends of Scrip's Stock Scan monthly league table.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC099951

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel